eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2019
vol. 36
 
Share:
Share:
more
 
 
abstract:
Original paper

Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit

Ewa Cichocka-Jarosz, Marcin Stobiecki, Marita Nittner-Marszalska, Urszula Jedynak-Wąsowicz, Piotr Brzyski, Immunotherapy Section of the Polish Society of Allergology Working Group (PTA)

Adv Dermatol Allergol 2019; XXXVI (3): 346-353
Online publish date: 2019/06/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Venom immunotherapy treatment (VIT) is the only causal treatment of hymenoptera venom anaphylaxis, which aims to provide long-lasting immunoprotection against severe reactions to subsequent stings.

Aim
To reassess the compliance of VIT procedures in the Polish allergy centres with the European guidelines.

Material and methods
A structured questionnaire survey conducted in all 33 VIT-centres. The response rate was 94%.

Results
The ultrarush initial protocol was the most common protocol (71%, n = 22), usually lasting for 3.5 h (50%, n = 7). The most frequent (36%, n = 11) time interval from the initial to the first maintenance dose (MD) was 14 days, ranging from 7 to 35 days. All centres used an MD of 100 µg. The most frequent time interval between subsequent MDs was 4 weeks (58%, n = 18). Five years’ of VIT was declared by 71% (n = 22). Before the termination of treatment, more than half of the centres (58%, n = 18) performed sIgE and almost half (42%, n = 13) performed skin tests. To confirm VIT efficacy, few centres (26%, n = 8) conducted the sting challenge. About half of centres provided the patients with an adrenalin auto-injector both at the time of initial diagnostics and at the end of treatment. More than half (55%, n = 17) used antihistamines in all patients. Almost half (45%, n = 14) declared to stop treatment with -blockers and almost one fourth (23%, n = 7) discontinued angiotensin-converting-enzyme inhibitors.

Conclusions
In the most important procedures, there is a very high compliance with the guidelines. In the areas where the guidelines are not precise, we observed a large spread of results.

keywords:

venom allergy, immunotherapy, national survey

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe